Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2012

View Archived Issues

Tragara multikinase inhibitor may be beneficial to treat triple-negative breast cancer

Phase II data presented on PEGylated therapy in previously treated metastatic breast cancer

Phase II results disclosed on PD-0332991

Dual ERK inhibitor shows promise as triple-negative breast cancer therapy

Two Cellceutix products expected to enter clinic this year

Phase II trial assesses proprietary Exelixis drug in metastatic breast cancer

New HCV NS5A inhibitors disclosed by Presidio Pharmaceuticals

Apricus Biosciences and Stellar Pharmaceuticals sign license agreement for MycoVa

Dosing completed in phase II trial of low-dose oral Proellex

Isotechnika licenses voclosporin to Vifor Pharma for certain regions

Euroscreen prepares new agents for diabetes and associated conditions

Novel inhibitors of cytochrome P450 enzymes synthesized by Angion Biomedica

Arrow Therapeutics claims novel HCV NS5B inhibitors

ACH-1625 receives FDA fast track status

Enanta Pharmaceuticals designs new compounds for hepatitis C virus infection

Quark Pharmaceuticals reports first-in-human data on siRNA drug candidate

Researchers at Albany Molecular Research patent novel GlyT-1 inhibitors

Cardiokine acquired by Cornerstone Therapeutics

Alkermes reports phase I/II ALKS-5461 study results

Alnylam reports preliminary results from phase I ALN-PCS trial

Alchemia treats first patient in pivotal phase III HA-irinotecan trial

Celldex begins phase II study of rindopepimut

PolyMedix completes enrollment in PMX-30063 study

Acacia Pharma begins phase II APD-421 trial

Biogen Idec and Isis enter collaboration on antisense drug for SMA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...